Plus Therapeutics upgraded by D. Boral Capital with a new price target
$PSTV
Medical/Dental Instruments
Health Care
D. Boral Capital upgraded Plus Therapeutics from Hold to Buy and set a new price target of $5.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/3/2025 | $5.00 | Hold → Buy | D. Boral Capital |
| 3/17/2025 | $9.00 | Buy | D. Boral Capital |
HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced two new hires to its team for CNSide Diagnostics, LLC, its wholly-owned subsidiary. "We are strategically building the team to bolster our capabilities as we scale up our laboratory operations to address the largely untapped $6billion+ U.S. addressable market for CNSide cerebrospinal fluid assay for metastatic CNS cancers, all the while maintaining the highest quality standards," said Russ Bradley, CNSide Diagnos
Cohort 1 data from multiple dose ReSPECT- Leptomeningeal Metastases (LM) trial showed no dosage limiting toxicity ReSPECT-Glioblastoma (GBM) trial of REYOBIQ as a novel therapeutic for recurrent GBM demonstrated promising safety and efficacy signal, supporting continued Phase 2 enrollment and investigation MRI combined with SPECT imaging biomarkers effectively evaluate overall survival response with REYOBIQ in recurrent GBM treatment and help guide personalized patient planning HOUSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologie
HOUSTON, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the acceptance of an abstract for poster spotlight (with oral) presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS), being held on December 9-12, 2025, in San Antonio, TX. Poster Spotlight Presentation:TitleRhenium (186Re) obisbemeda (rhenium nanoliposome, 186RNL) for the treatment of leptomeningeal metastases (LM): Phase 1 dose escalation study results PresenterAndrew Brenner, M.D., Ph.D., Professor and Kolit
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
4/A - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
10-Q - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
D. Boral Capital upgraded Plus Therapeutics from Hold to Buy and set a new price target of $5.00
D. Boral Capital initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $9.00
HC Wainwright initiated coverage of Plus Therapeutics with a rating of Buy
Expands commercial readiness and diagnostic, manufacturing footprint Appoints new leadership in commercial strategy and technical operations HOUSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces continued operational execution and commercial progress in the launch of its wholly owned subsidiary, CNSide Diagnostic LLC's, Cerebrospinal Fluid (CSF) Tumor Cell Enumeration laboratory developed test (LDT). Recent accomplishments include expansion of the CNSide manufacturing footprint,
HOUSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the appointment of Kyle Guse, J.D., M.B.A. to the Company's Board of Directors where he will serve as chair of the Audit Committee and on the Compensation Committee. "Kyle's decades of financial, transactional and operational experience in our industry will make an immediate and positive impact to Plus' board of directors," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "Furthermore, in his
AUSTIN, Texas, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced the appointment of Michael Rosol, Ph.D., as Chief Development Officer. Dr. Rosol will lead the company's clinical, pre-clinical, and biomarker development activities. "Plus is at an inflection point in our clinical development as we move from mid-stage to pivotal trials next year," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "Mike's background in oncology and radiotherapeutic
US market introduction of the CNSide® CSF diagnostics platform, with first national coverage agreement with UnitedHealthcare Presented positive RESPECT-LM Ph1 clinical trial results HOUSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the third quarter ended September 30, 2025 and provides an overview of recent and upcoming business highlights. "Our team continues to execute solidly across the three most important business verticals: diagnost
Announced CNSide® CSF assay platform launch timeline Initiated the REYOBIQ dose optimization trial for patients with leptomeningeal metastases HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the second quarter ended June 30, 2025, and provides an overview of recent and upcoming business highlights. "The second quarter of 2025 marked steady execution and progress on our key strategic initiatives: clinical development o
U.S. commercial rollout of novel diagnostic platform to begin second half 2025 Underserved CNS cancer diagnostic U.S. market opportunity estimated to be in excess of $6 billion Management to host a conference call today at 9am ET HOUSTON, June 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, will provide a business update for its wholly-owned subsidiary, CNSide Diagnostics, LLC ("CNSide"). The proprietary CNSide Cerebrospinal Fluid (CSF) Assay Platform is designed and intended for patients s
SC 13G - PLUS THERAPEUTICS, INC. (0001095981) (Subject)
SC 13G/A - PLUS THERAPEUTICS, INC. (0001095981) (Subject)
SC 13G/A - PLUS THERAPEUTICS, INC. (0001095981) (Subject)